Nuvectis Pharma, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
NVCT Nasdaq 2830 www.nuvectis.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Nuvectis Pharma, Inc.

Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC - Dec 17th, 2025 5:00 am
Nuvectis Pharma, Inc.'s (NASDAQ:NVCT) market cap rose US$18m last week; retail investors who hold 44% profited and so did insiders - Dec 5th, 2025 5:15 am
Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC - Nov 25th, 2025 6:00 am
Director of Nuvectis Pharma Juan Sanchez Buys 20% More Shares - Nov 8th, 2025 5:00 am
CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights - Nov 4th, 2025 6:15 am
Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights - Nov 4th, 2025 5:30 am
Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Oct 27th, 2025 6:00 am
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Oct 16th, 2025 6:00 am
Nuvectis Pharma (NASDAQ:NVCT) Is In A Good Position To Deliver On Growth Plans - Oct 15th, 2025 6:08 am
Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors - Sep 25th, 2025 6:00 am
Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference - Sep 4th, 2025 5:30 am
Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900 - Aug 11th, 2025 2:30 pm
Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights - Aug 5th, 2025 5:30 am
Nuvectis Pharma cuts NXP800 in ovarian cancer after early failure - Aug 4th, 2025 5:41 am
Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study - Jul 31st, 2025 5:45 am
Nuvectis Pharma Insiders Added US$2.50m Of Stock To Their Holdings - Jul 29th, 2025 4:24 am
Nuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900's Potential as a Combination Partner with Leading Therapies - Jul 8th, 2025 6:00 am
Insiders of Nuvectis Pharma, Inc. (NASDAQ:NVCT) must be disappointed as stock fell 10% after recent purchases - Jun 18th, 2025 6:17 am
Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference - May 16th, 2025 2:35 pm
Does Nuvectis Pharma (NVCT) Have the Potential to Rally 108.79% as Wall Street Analysts Expect? - May 9th, 2025 7:55 am